Institut für Molekulare Immunologie, Helmholtz-Zentrum München, München, Germany.
Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
Eur J Immunol. 2015 Sep;45(9):2593-601. doi: 10.1002/eji.201445375. Epub 2015 Jul 7.
Little is known on the control of lymphomas by NK cells. Here, we study the role of the NK group 2D (NKG2D) receptor for the immunosurveillance of lymphoma. By using transplantable tumors as well as a λ-myc-transgenic model of endogenously arising lymphoma and NKG2D-deficient mice, we show that NK cells eliminate tumor cells in vivo after receiving two signals. One step involved the activation of NK cells giving rise to IFN-γ expression, which was effected by MHCI(low) tumor cells or DCs. However, this was necessary but not sufficient to mediate cytotoxicity. Triggering cytotoxicity additionally required a second step, which could be mediated by engagement of the NKG2D receptor. Thus, NKG2D-deficient NK cells could become activated in vivo, but they were not able to reject transplanted lymphomas or to degranulate in animals bearing autochthonous lymphomas. Tumor growth in NKG2D-deficient λ-myc-transgenic mice was significantly accelerated compared to NKG2D-competent animals. Whereas the latter developed tumors that lost expression of NKG2D ligands (NKG2D-L) in late disease stages, this did not occur in NKG2D-deficient mice. This indicates that NK cells and the NKG2D receptor play a role for control of lymphomas and that selection for NKG2D-L loss mutants provides a mechanism of tumor escape.
关于自然杀伤 (NK) 细胞对淋巴瘤的控制作用知之甚少。在这里,我们研究了 NK 细胞群 2D(NKG2D)受体在淋巴瘤免疫监视中的作用。通过使用可移植肿瘤以及内源性发生淋巴瘤的 λ-myc 转基因模型和 NKG2D 缺陷小鼠,我们表明 NK 细胞在接受两个信号后可以在体内消除肿瘤细胞。一个步骤涉及 NK 细胞的激活,导致 IFN-γ 的表达,这是由 MHC I(低)肿瘤细胞或 DC 引起的。然而,这是必要的,但不足以介导细胞毒性。触发细胞毒性还需要第二步,这可以通过 NKG2D 受体的结合来介导。因此,NKG2D 缺陷的 NK 细胞可以在体内被激活,但它们不能排斥移植的淋巴瘤,也不能在患有自发性淋巴瘤的动物中脱颗粒。与 NKG2D 功能正常的动物相比,NKG2D 缺陷的 λ-myc 转基因小鼠中的肿瘤生长明显加快。后者发展的肿瘤在疾病晚期会失去 NKG2D 配体(NKG2D-L)的表达,而 NKG2D 缺陷小鼠则不会发生这种情况。这表明 NK 细胞和 NKG2D 受体在控制淋巴瘤方面发挥作用,并且选择 NKG2D-L 缺失突变体提供了一种肿瘤逃逸的机制。